Senior Scientist, Single Cell Target Discovery/Validation

Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with investors Samsara BioCapital and Sheatree Capital. The company is developing a best-in-class logic-gate technology to spur a new generation of cell therapies for patients with solid tumors. Link’s “AND” gates require two cancer-associated targets for a CAR T cell to attack cancer cells, thereby providing specificity for killing of tumor cells while sparing healthy tissue. Combined with additional technologies under development, Link will advance a suite of exciting internal therapeutic programs while exploring opportunities for value creation with strategic partners.